| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
28,633 |
2,537 |
$671K |
| 83970 |
|
1,520 |
1,306 |
$201K |
| 82728 |
|
1,550 |
1,314 |
$189K |
| 83550 |
|
1,526 |
1,286 |
$104K |
| 83540 |
|
1,560 |
1,305 |
$84K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
31,546 |
1,657 |
$76K |
| 82108 |
|
152 |
111 |
$28K |
| A4657 |
Syringe, with or without needle, each |
1,657 |
1,434 |
$9K |
| J1756 |
Injection, iron sucrose, 1 mg |
3,190 |
858 |
$5K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
10,450 |
926 |
$4K |
| 85041 |
|
1,393 |
1,208 |
$966.97 |
| 85048 |
|
1,388 |
1,204 |
$753.14 |
| 87340 |
|
32 |
27 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
307 |
122 |
$0.00 |
| 86706 |
|
31 |
26 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
25 |
25 |
$0.00 |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
27 |
14 |
$0.00 |
| 90662 |
|
27 |
27 |
$0.00 |